Precision medicine directed therapy enabling long-term survival in medulloblastoma: a case report
-
By
-
Laura Vazquez
-
Jonathan Lerch
-
Divya Gandra
-
Abigail Moore
-
Jessica Lincoln
-
Abhinav B. Nagulapally
-
Suzanne Treadway
-
Krishnamoorthy Thamburaj
-
Valerie Brown
-
Giselle Saulnier Sholler
-
July 14, 2026
Clinical Scorecard: Targeted therapy in precision medicine leads to extended survival in a case of medulloblastoma: a clinical report
At a Glance
| Category | Detail |
|---|
| Condition | Medulloblastoma (MB) |
| Key Mechanisms | Targeted therapy based on genomic sequencing and precision medicine analysis. |
| Target Population | Children diagnosed with subgroup-SHH medulloblastoma. |
| Care Setting | Pediatric oncology clinical trial setting. |
Key Highlights
- Subgroup-SHH of medulloblastoma has a poor prognosis with a 10-30% long-term survival rate at relapse.
- The case presented involved a 6-year-old male with recurrent medulloblastoma treated with targeted therapy.
- Genomic sequencing guided the selection of targeted therapies leading to a complete tumor response.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of medulloblastoma is confirmed through pathology and imaging.
Management
- Initial treatment includes surgery, chemotherapy, and autologous stem cell transplant.
Monitoring & Follow-up
- Regular imaging and clinical assessments are necessary to detect recurrence.
Risks
- Relapsed medulloblastoma has a high risk of poor outcomes and increased toxicity from treatments.
Patient & Prescribing Data
Children with relapsed or refractory medulloblastoma.
Precision medicine approaches can optimize treatment efficacy while minimizing toxicity.
Clinical Best Practices
- Utilize genomic sequencing to inform treatment decisions in relapsed medulloblastoma.
- Consider enrollment in clinical trials for innovative treatment options.
Related Resources & Content
